- Home
- RDZN vs NGEN Comparison
RDZN vs NGEN Comparison
Compare RDZN & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | RDZN | NGEN |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | United States | Canada |
| Employees | 308 | 9 |
| Industry | Blank Checks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.4M | 175.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RDZN | NGEN |
|---|---|---|
| Price | $1.71 | $1.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | 618.3K | ★ 1.2M |
| Earning Date | 02-12-2026 | 04-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $33.77 | N/A |
| Revenue Next Year | $51.46 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.81 | $1.87 |
| 52 Week High | $2.56 | $5.93 |
Technical Indicators
Market Signals| Indicator | RDZN | NGEN |
|---|---|---|
| Relative Strength Index (RSI) | 47.14 | 25.23 |
| Support Level | $1.60 | N/A |
| Resistance Level | $1.99 | $4.52 |
| Average True Range (ATR) | 0.14 | 0.15 |
| MACD | -0.03 | -0.08 |
| Stochastic Oscillator | 8.82 | 1.05 |
Price Performance
Historical ComparisonAbout RDZN Roadzen Inc.
Roadzen Inc is an insurance technology company on a mission to transform auto insurance powered by AI. Its clients comprise insurers, fleets, and carmakers to small fleets, brokers, and insurance agents that use Roadzen's technology to build new products, sell insurance, process claims, and improve road safety. The company's work in telematics and computer vision has earned recognition as an AI innovator by publications such as Forbes, Fortune, and Financial Express.
About NGEN NervGen Pharma Corp. Common stock
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.